Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Non Operating Income (2019 - 2025)

Historic Non Operating Income for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$41.3 million.

  • BridgeBio Pharma's Non Operating Income fell 25014.18% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$194.1 million, marking a year-over-year decrease of 29791.59%. This contributed to the annual value of $50.8 million for FY2024, which is 21067.54% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Non Operating Income of -$41.3 million as of Q3 2025, which was down 25014.18% from -$47.4 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Non Operating Income registered a high of $100.0 million during Q2 2024, and its lowest value of -$65.2 million during Q1 2025.
  • In the last 5 years, BridgeBio Pharma's Non Operating Income had a median value of -$11.5 million in 2021 and averaged -$4.0 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Non Operating Income soared by 106310.96% in 2022, and later crashed by 66728.27% in 2024.
  • BridgeBio Pharma's Non Operating Income (Quarter) stood at $59.0 million in 2021, then crashed by 119.22% to -$11.3 million in 2022, then skyrocketed by 162.52% to $7.1 million in 2023, then plummeted by 667.28% to -$40.2 million in 2024, then fell by 2.67% to -$41.3 million in 2025.
  • Its Non Operating Income was -$41.3 million in Q3 2025, compared to -$47.4 million in Q2 2025 and -$65.2 million in Q1 2025.